S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02%
Next Bullish Trade
Sign in
ATAI

AtaiBeckley Inc. ATAI

$7.22 +0.07 (+0.98%)
Blow-off · +3.90σ Hot zone

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · ATAI

Momentum reads · latest daily bar
Last
$7.22
+0.07 (+0.98%)
Mkt cap
$2.7B
Healthcare
RSI(14)
75.3
overbought
Stochastic %K
90.7
overbought
MFI(14)
92.0
overbought
ADX(14)
31.3
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.0B $-0.0B $-0.0B $-0.0B -3121.8% -3161.3%
2025-12-31 $0.0B $-0.5B $-0.0B $-0.0B -51108.2% -3691.7%
2025-09-30 $0.0B $-0.1B $-0.0B $-0.0B -8154.1% -3792.7%
2025-06-30 $0.0B $-0.0B $-0.0B $-0.0B -3856.6% -3511.1%
2025-03-31 $0.0B $-0.0B $-0.0B $-0.0B -1699.7% -1308.2%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare ATAI vs peers

Line ATAI up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing ATAI no peers yet — add up to 4 below

Add tickers to compare with ATAI

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 19 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-03-06 -1.73 -0.11 -1441.6% +14.8%
2025-11-12 -0.28 -0.12 -125.3% -4.6%
2025-08-14 -0.14 -0.12 -18.3% -3.2%
2025-05-14 -0.15 -0.18 +16.7% +14.0%
2025-03-17 -0.24 -0.15 -60.0% -7.5%
2024-11-13 -0.16 -0.16 +1.5%
2024-08-13 -0.36 -0.16 -129.8% -4.1%
2024-05-15 -0.17 -0.18 +5.6% -9.3%
2024-03-28 -0.12 -0.16 +26.1% -5.6%
2023-11-14 0.25 -0.20 +226.6% -4.4%
2023-08-10 -0.21 -0.21 -1.6% -1.8%
2023-05-11 -0.21 -0.22 +3.4% -3.1%
2023-03-24 -0.28 -0.23 -23.3% +9.6%
2022-11-10 -0.22 -0.24 +8.1% -6.1%
2022-08-15 -0.24 -0.24 +0.1% +1.9%
2022-05-16 -0.24 -0.25 +5.7% +2.0%
2022-03-30 -0.62 -0.25 -150.8% -4.7%
2021-11-15 -0.21 -0.22 +6.5% -4.4%
2021-08-16 -0.37 -0.17 -115.3% +4.3%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
ATAI $3B -15.8 765.8 -20.0 13.3 -38.7% -2.08%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0%
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 17.17%

HolderShares% out
Deep Track Capital, Lp 12,000,000 3.26%
Vanguard Capital Management LLC 11,761,398 3.19%
UBS Group AG 7,426,867 2.02%
Blackrock Inc. 6,835,300 1.86%
Adage Capital Partners GP L.L.C. 5,642,758 1.53%
Susquehanna International Group, LLP 5,286,326 1.44%
Millennium Management Llc 4,364,096 1.19%
Morgan Stanley 3,852,772 1.05%
Candriam S.C.A. 3,086,379 0.84%
Qube Research & Technologies Ltd 2,891,942 0.79%

Insider activity · 90d

9 buys / 1 sells · ratio 9.0 · Finnhub

  • HERSHBERG ROBERT M 404,869
  • HERSHBERG ROBERT M 48,858
  • HERSHBERG ROBERT SELL 100,000 @ $4.96
  • HERSHBERG ROBERT M 100,000 @ $1.35
  • HERSHBERG ROBERT M 48,858 @ $1.35
  • Hoffman John Francis BUY 121,968
  • Angermayer Christian BUY 121,968
  • Smiley Andrea Heslin BUY 121,968
  • Braunstein Scott BUY 86,095
  • Braunstein Scott BUY 121,968

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$7.5
Mean
$12.59375
High
$25.0
Analysts
8
Recommendation distribution · period 2026-07-01
6
14
1
Revision trend (2026-04-01 → 2026-07-01): net 19 → 20 +1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-16 8-K view ·
4 2026-07-09 FORM 4 view ·
4 2026-06-29 FORM 4 view ·
4 2026-06-29 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
8-K 2026-06-08 8-K view ·
8-K 2026-06-03 8-K view ·
10-Q 2026-05-12 10-Q view ·
8-K 2026-05-12 8-K view ·
4 2026-04-22 FORM 4 view ·
DEF 14A 2026-04-22 DEF 14A view ·
4 2026-04-10 FORM 4 view ·
4 2026-03-24 FORM 4 view ·
4 2026-03-13 FORM 4 view ·
8-K 2026-03-09 8-K view ·
8-K 2026-03-06 8-K view ·
10-K 2026-03-06 10-K view ·
8-K 2026-03-06 8-K view ·
8-K 2026-02-26 8-K view ·
8-K 2026-02-19 8-K view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
8-K 2026-01-08 8-K view ·
4 2026-01-06 FORM 4 view ·

About ATAI

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and…

Options picks · ATAI

ITM + OTM ideas from the latest scan

Loading…

Congress trades · ATAI

STOCK Act disclosures

Loading…

SEC filings & insiders · ATAI

EDGAR · live

Loading…

Holders · ATAI

Institutions & insider activity

Loading…